A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Phase of Trial: Phase III
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms ANITSCHKOW
- Sponsors Amgen
- 06 Oct 2017 Planned End Date changed from 20 Feb 2018 to 6 Apr 2018.
- 06 Oct 2017 Planned primary completion date changed from 20 Feb 2018 to 6 Apr 2018.
- 10 Jun 2017 Biomarkers information updated